EI
RLMD icon

EAM Investors’s Relmada Therapeutics RLMD Stock Holding History

EAM Investors’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$612K Sell
88,447
-42,488
-32% -$297K 0.05% 264
2026
Q1 		$911K Sell
130,935
-31,617
-19% -$150K 0.11% 217
2025
Q4 		$785K Buy
+162,552
New +$545K 0.09% 231

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EAM Investors's RLMD Position: Q2 2026 in Review

EAM Investors reduced its Relmada Therapeutics (RLMD) stake by 32% in Q2 2026, selling an estimated $297K and leaving 88,447 shares worth $612K. The position accounts for 0.05% of the portfolio, ranked #264.

EAM Investors first reported a position in RLMD in Q4 2025 and has held it in 3 quarters since. The position peaked at $911K in Q1 2026. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • EAM Investors held 88,447 shares of Relmada Therapeutics worth $612K as of Q2 2026.
  • EAM Investors sold 42,488 Relmada Therapeutics shares in Q2 2026, an estimated $297K.
  • Relmada Therapeutics made up 0.05% of EAM Investors's portfolio in Q2 2026, its #264 holding.
  • EAM Investors first reported a position in Relmada Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • EAM Investors's Relmada Therapeutics position peaked at $911K in Q1 2026.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on EAM Investors's 13F filing for Q2 2026, filed 13 Aug 2026.